Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090090 · ClinicalTrials.gov registry record · Phase 2
Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT00090090 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 114 participants.
The verdict
NCT00090090, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).
Interventions
- DRUG Elsamitrucin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090090
The ClinicalTrials.gov registry entry for NCT00090090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elsamitrucin is the first listed.
NCT00090090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090090 about?
NCT00090090 is a clinical study titled "Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma". To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).
What is the current status of trial NCT00090090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2004-04. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00090090?
The interventions under investigation include: Elsamitrucin (DRUG).
Who is sponsoring clinical trial NCT00090090?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.